You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Deflazacort - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for deflazacort and what is the scope of patent protection?

Deflazacort is the generic ingredient in one branded drug marketed by Ptc Therap and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for deflazacort. One supplier is listed for this compound.

Summary for deflazacort
US Patents:0
Tradenames:1
Applicants:1
NDAs:2
Drug Master File Entries: 3
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 75
Clinical Trials: 23
Patent Applications: 6,820
What excipients (inactive ingredients) are in deflazacort?deflazacort excipients list
DailyMed Link:deflazacort at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for deflazacort
Generic Entry Dates for deflazacort*:
Constraining patent/regulatory exclusivity:
TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
Dosage:
SUSPENSION;ORAL
Generic Entry Dates for deflazacort*:
Constraining patent/regulatory exclusivity:
TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for deflazacort

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Parc de Salut MarPhase 1
FibroGenPhase 3
Catabasis PharmaceuticalsPhase 1

See all deflazacort clinical trials

Pharmacology for deflazacort

US Patents and Regulatory Information for deflazacort

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ptc Therap EMFLAZA deflazacort TABLET;ORAL 208684-002 Feb 9, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Ptc Therap EMFLAZA deflazacort TABLET;ORAL 208684-001 Feb 9, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Ptc Therap EMFLAZA deflazacort SUSPENSION;ORAL 208685-001 Feb 9, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Ptc Therap EMFLAZA deflazacort TABLET;ORAL 208684-002 Feb 9, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Ptc Therap EMFLAZA deflazacort TABLET;ORAL 208684-003 Feb 9, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Ptc Therap EMFLAZA deflazacort TABLET;ORAL 208684-003 Feb 9, 2017 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.